Section Arrow
VTVT.NASDAQ
- vTv Therapeutics
Quotes are at least 15-min delayed:2026/02/23 19:32 EST
After Hours
Last
 35.135
+0.525 (+1.52%)
Bid
31.25
Ask
38.2
High 35.135 
Low 35.135 
Volume
Regular Hours (Closed)
Last
 34.61
+0.31 (+0.90%)
Day High 
35.9099 
Prev. Close
34.3 
1-M High
42.4599 
Volume 
122 
Bid
31.25
Ask
38.2
Day Low
34 
Open
34.02 
1-M Low
28.84 
Market Cap 
135.07M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 34.43 
20-SMA 34.84 
50-SMA 35.97 
52-W High 44 
52-W Low 14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.30/-3.80
Enterprise Value
135.07M
Balance Sheet
Book Value Per Share
17.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.02M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4084 -0.01215 -2.89%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.8501 +0.0301 +0.31%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.26 +0.09 +1.10%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.86 +0.06 +3.33%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.3814 -0.0286 -6.98%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.